Nestlé’s $255 Million Recall Bill Arrives as Coffee Deals Reshape the Portfolio

Nestlé's infant formula recall cost nearly 1% of organic growth, but coffee strength and Blue Bottle sale to Luckin's owner signal a strategic pivot to high-margin scalable products.

The cost of Nestlé’s worst-ever product recall is now quantified, and it cuts deep into first-quarter performance — but the Swiss giant is already moving to offset the damage with a strategic exit from a premium coffee chain.

The January 2026 recall of infant formula, triggered by the Cereulid toxin from a global industrial supplier, wiped $255 million off sales. Direct costs for refunds and supply disruptions hit 200 million Swiss francs, with roughly half stemming from a collapse in customer demand. Bernstein Research calculates that without the infant nutrition drag, Nestlé’s organic growth would have clocked in at 4.4 percent rather than the reported 3.5 percent — meaning the recall alone cost nearly a full percentage point of expansion.

Yet the headline numbers surprised analysts on the upside. Group revenue fell 5.7 percent year-on-year to 21.3 billion francs, but that decline was largely a currency story: headwinds of more than nine percent swallowed pricing gains. Underlying organic growth of 3.5 percent beat expectations, thanks to a powerful performance from the coffee division.

Coffee carries the quarter

The coffee segment delivered organic growth of 9.3 percent. Nescafé soluble coffee and Starbucks-licensed products both posted strong results across North and South America. Emerging markets added another layer of support, growing 6.8 percent organically. Real internal growth — a measure of volume sold — remained positive across every category except infant nutrition, which slumped to minus 3.5 percent.

That coffee momentum is also driving portfolio decisions. Nestlé has agreed to sell its Blue Bottle chain to Centurium Capital, a Chinese private-equity firm that already controls a majority stake in Luckin Coffee. The deal covers more than 100 Blue Bottle cafés worldwide plus the associated consumer goods business. Financial terms were not disclosed, though Nestlé originally acquired the Oakland-based chain in 2017 for over $700 million.

The rationale is straightforward: running company-owned cafés is capital-intensive and tied to local real estate trends. Nestlé is pivoting toward high-margin, easily scalable products like instant coffee. The company will retain the rights to Blue Bottle-branded Nespresso capsules, keeping a foothold in the premium pod market without the operational overhead of physical stores. The transaction is expected to close in the first half of 2026.

A broader cleanup under way

CEO Philipp Navratil is using the same logic across the portfolio. Nestlé is actively seeking partners for its water division and buyers for its standard nutritional supplements business. In Germany, the group recently exited its majority stake in spice startup Ankerkraut after four years, with the founders buying back their shares.

The Blue Bottle sale fits a pattern of shedding assets that require heavy local infrastructure while doubling down on categories that can scale globally with minimal friction. The coffee division’s strong quarter validates that approach — at least for now.

Recovery in sight, but China remains a question

CFO Anna Manz reports early signs of improvement in infant nutrition and expects a full recovery by year-end. Product availability has already normalized. Whether Nestlé will pursue legal action against the supplier remains an open question; Navratil declined to comment.

For the full year, management is holding to its targets: organic growth of three to four percent, an improved underlying trading operating profit margin, and free cash flow above nine billion francs. China, Nestlé’s second-largest market, is expected to see a turnaround from the second half of the year.

The stock tells a more cautious story. Trading at 79.44 francs, the shares sit roughly 16 percent below their 52-week high of 94.88 francs. Since the start of the year, the equity has lost nearly six percent. The recovery narrative, for now, remains a promise for the second half — backed by coffee, portfolio discipline, and the hope that the recall is firmly in the rearview mirror.